Selected Publications
Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial (abstract). Blood 2024; 144 (Supplement 1): 3210.
A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes (abstract). Blood 2024; 144 (Supplement 1): 532.
Improvement in quality of life in MDS patients who become transfusion independent after treatment. Leuk Lymphoma. 2024 Nov 9:1-10. doi: 10.1080/10428194.2024.2422844.
Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial (abstract). Blood 2023; 142 (Supplement 1): 6479.
Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS Study. Cancers (Basel) 2023 Jun 22;15(13):3296.
Raising the standards of patient-centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS-RIGHT project. Cancer Medicine. 2023;12:7529–7539.
Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned. Blood Reviews 2021; Volume 50, Article 100851.
Peri-transfusion quality of life assessment for patients with myelodysplastic syndromes. Transfusion. 2021 Oct; 61(10):2830-2836.
Validation of the QUALMS Questionnaire to Assess Health-Related Quality of Life in European and Israeli Patients with Myelodysplastic Syndromes: Results from the MDS-Right Project [abstract]. Blood. 2021.
Feasibility of Peri-Transfusion Quality of Life Assessment for Patients with Myelodysplastic Syndromes [abstract]. Blood. 2020.
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes. J Patient Rep Outcomes. 2020 Aug 26;4(1):69.
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica 2016; 101(6): 781-8.
Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood 2014; 123(3): 451-2.
A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes (abstract). Blood 2024; 144 (Supplement 1): 532.
Improvement in quality of life in MDS patients who become transfusion independent after treatment. Leuk Lymphoma. 2024 Nov 9:1-10. doi: 10.1080/10428194.2024.2422844.
Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial (abstract). Blood 2023; 142 (Supplement 1): 6479.
Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS Study. Cancers (Basel) 2023 Jun 22;15(13):3296.
Raising the standards of patient-centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS-RIGHT project. Cancer Medicine. 2023;12:7529–7539.
Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned. Blood Reviews 2021; Volume 50, Article 100851.
Peri-transfusion quality of life assessment for patients with myelodysplastic syndromes. Transfusion. 2021 Oct; 61(10):2830-2836.
Validation of the QUALMS Questionnaire to Assess Health-Related Quality of Life in European and Israeli Patients with Myelodysplastic Syndromes: Results from the MDS-Right Project [abstract]. Blood. 2021.
Feasibility of Peri-Transfusion Quality of Life Assessment for Patients with Myelodysplastic Syndromes [abstract]. Blood. 2020.
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes. J Patient Rep Outcomes. 2020 Aug 26;4(1):69.
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica 2016; 101(6): 781-8.
Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood 2014; 123(3): 451-2.